Introduction
The Wada test is a procedure generally used to establish hemispheric dominance of language and identify contralateral memory reserve prior to respective surgery for temporal lobe epilepsy. Between 2003 and there was an international shortage in the availability of amobarbital. As a result, alternative anaesthetics and methods for the Wada test were sought. 1 Since 2006, the alternative anaesthetic adopted for use in Beaumont Hospital is propofol. Propofol has been used as an anaesthetic for Wada testing in some centres prior to the shortage of amobarbital. [2] [3] [4] Mikuni et al. 5 evaluated the adverse effects associated with intracarotid propofol testing in a mixed neurosurgical sample (n = 58) and found that 33% of their patients (19 patients) exhibited side effects to propofol. They sub-classified side effects based on severity into grades one, two and three (illustrated in Table 1 ). Mikuni et al. 5 reported six patients exhibiting Grade 1 side effects, six patients with Grade 2 side effects and seven with Grade 3 side effects.
Mikati et al. 6 compared amobarbital (n = 25) and propofol (n = 15) as anaesthetics in a sample of neurosurgical patients undergoing a Wada test with respect to time to the return of motor power and time to return of verbal and non-verbal responses. They concluded that there was no significant difference between amobarbital and propofol with respect to time to motor power restoration or verbal and non-verbal responses. More recently, a full review of alternative anaesthetics used in Wada testing 7 found that propofol resulted in an increase in tone and rhythmic twitching that hindered the completion of the procedure. This emphasises the need for further investigation to assess propofol's use as an anaesthetic agent in the Wada procedure. The present study endeavoured to compare the usefulness of propofol as an alternate anaesthetic to amobarbital for use in the Wada test.
Methods
The data for the present study was acquired retrospectively from records of patients who underwent a 
Wada procedure
The cerebral angiography procedure associated with achieving a Wada test is outlined elsewhere. 8 The Wada test is conducted in a radiography suite, which is fully equipped to deal with any complications that may arise during the procedure. Once hemiplegia is induced, language functions are assessed by presenting the patient with a range of stimuli, which they are asked to name. Patients are then asked to attend to several receptive speech tasks and read a number of sentences. If the patient's dominant hemisphere is anaesthetised, the patient will be unable to respond. Once these tasks are completed, patients are presented with 16 separate visual and verbal stimuli, which they are asked to remember. The duration of anaesthetic affect is measured by assessing hemiplegia at planned, regular intervals throughout the procedure. After the protocol has been completed, there is a time delay of 10 min before the recall phase of the memory component of the test. This consists of a four-choice alternate recognition task in which patients are shown 16 sets of either four pictures or four words, each set including a picture or word previously presented during the test. Patients are encouraged to make their best guess. In Beaumont Hospital it is standard practice to only conduct a unilateral Wada test. This is conducted ispilateral to the proposed site of resection, this is now standard practice in several international epilepsy centres. 9 There is ongoing debate internationally regarding whether the side of injection should ipsilateral or contralateral to the intended area of resection.
Results

Demographic characteristics
In total, 129 Wada procedures were reviewed. The sample consisted of 57 males and 72 females. The age range in the propofol group was 21-60 years with a mean age of 38.37 years. The age range in the amobarbital group was 17-61 years with a mean age of 37.90 years. The characteristics of the sample with respect to the Wada test are as follows, 54 patients underwent a Wada test using propofol, of these 28 patients underwent an inject right, test left Wada procedure, 26 patients underwent an inject left, test right Wada procedure. The remaining 75 underwent the procedure using amobarbital, of this group 40 patients underwent an inject right, test left Wada procedure, 35 patients underwent an inject left, test right Wada procedure. All of the patients reviewed for this study were pre-surgical candidates for selective anterior temporal lobectomy due to drug resistant epilepsy.
Chi square and t-test analyses indicated that there was no significant difference between the propofol and amobarbital patient groups with respect to gender (Chi square = 1.123, df = 1, p = .263), handedness (Chi square = 1.307, df = 1, p = .193) or age at time tested (t = .269, df = 149, p = .515).
An independent samples t-test examining the difference in length of time to end of hemiplegia between amobarbital and propofol was conducted . This was also found not to be significant (t = 1.346, p = .181, df = 128). A further two independent samples ttests were also conducted to determine if there was a significant difference in memory scores with regard to amobarbital and propofol based on side of injection. There was not found to be any significant difference (t = .119, df = 50.3, p = .905) for left sided injections between amobarbital (M = 9.77, SD = 4.6) and propofol (M = 9.92, SD = 5.1). However, there was found to be a significant difference (t = 2.81, df = 56.5, p = .007) between memory scores for right sided injections between amobarbital (M = 11.77, SD = 4.72) and propofol (M = 14.19, SD = 2.13). The correlation between the length of time to end of hemiplegia and memory score was calculated for each drug and no significant relationships were found for either propofol (r = .142, N = 54, p = .306) or amobarbital (r = À.046, N = 75, p = .695).
With respect to the number of patients passing or failing the procedure, Chi-Square analysis indicated that there was no significant difference (Value = 1.643, df = 1, p = .201) between propofol (Pass = 81.5%, Fail = 18.5%) and amobarbital (Pass = 69.3%, Fail = 30.7%). Examination of Yates' Continuity Correction revealed no significant difference between the two anaesthetics with respect to Pass/Fail rates (Value = 1.159, df = 1, p = .282). A second Chi square test was performed to examine the difference between the two anaesthetics amobarbital and propofol with respect to the number of side effects experienced by each patient group, as categorised by Mikuni et al. 3 There was no significant difference in the number and type of side effects-experienced between either of the anaesthetics (Value = .157, df = 2, Asymp. Sig. = .924). A breakdown of the frequency and type side-effects experienced by the propofol and amobarbital groups is illustrated in Table 2 .
Discussion
The aim of the present study was to examine the suitability of propofol, as a replacement to amobarbital, for use in the Wada test. To date, this is the largest study to directly address this issue and also the first study to utilise an epilepsy only sample. There was no significant difference between propofol and amobarbital with respect to Pass/Fail rates, side effects or length of hemiplegia, thus indicating that propofol represents a suitable alternative to amobarbital for use in the Wada test. The number of side-effects observed in the present study are reduced compared to those observed by Mikuni et al. 5 particularly in relation to Grade 3 sideeffects. Mikuni et al. 5 reported Grade 3 side effects in seven patients, accounting for an incident rate of 12% of their sample, whereas in the present study, there were no Grade 3 side-effects observed in either the propofol or amobarbital group. There are two possible explanations for this. Firstly, Mikuni et al. 4 found the occurrence of Grade 3 side-effects to be correlated to a dosage of propofol of 15 Mg or more. In the present study, only 5 patients received a dose of propofol greater than 13 Mg. Mikuni et al. 4 also found there to be a correlation between the incidence of Grade 3 side-effects and patients older than 55 years. Again, in the present study, there were only 3 patients with an age greater than 55 years. Secondly, Mikuni et al's patient sample was mixed, consisting of patients with brain tumours, epilepsy and arteriovenous malformations, whereas the present study utilised a temporal lobe epilepsy only sample. Although not significant, it was observed that the period of hemiplegia induced by propofol was longer than the period of hemiplegia induced by amobarbital. Although this finding has no impact on the overall, the lengthier period of hemiplegia offered by propofol is beneficial during such a time constrained procedure. These findings provide good evidence that propofol represents a suitable alternative to amobarbital for use in the Wada procedure.
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